Broom Daniel C, Nitsche Joshua F, Pintar John E, Rice Kenner C, Woods James H, Traynor John R
Department of Pharmacology, University of Michigan Medical School, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0632, USA.
J Pharmacol Exp Ther. 2002 Nov;303(2):723-9. doi: 10.1124/jpet.102.036525.
Delta-opioid receptor-selective agonists produce antinociception and convulsions in several species, including mice. This article examines two hypotheses in mice: 1) that antinociception and convulsive activity are mediated through the same type of delta-receptor and 2) that greater delta-agonist efficacy is required for antinociception than for convulsive activity. Delta-mediated antinociception was evaluated in the acetic acid-induced abdominal constriction assay, which involves a low-intensity noxious stimulus; convulsive activity was indicated as a mild tonic-clonic convulsive episode followed by a period of catalepsy. In delta-opioid receptor knockout mice [DOR-1(-/-)], the nonpeptidic delta-agonists (+/-)-4-[(R*)-[(2S*,5R*)-2,5-dimethyl-4-(2-propenyl)-1- piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide hydrochloride (BW373U86) and (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N, N-diethylbenzamide (SNC80) failed to produce convulsive behavior demonstrating the absolute involvement of DOR-1 in this effect. In NIH Swiss mice expressing delta-opioid receptors, BW373U86 produced both antinociception and convulsive activity. These effects were antagonized by the putative delta(1)-receptor-selective antagonist 7-benzylidenenaltrexone and the putative delta(2)-receptor-selective antagonist naltriben. Tolerance developed to both the convulsive and antinociceptive effects of BW373U86. Tolerance to the convulsive, but not the antinociceptive, effects of BW373U86 was largely prevented when the antagonist naltrindole was given 20 min after each dose of the agonist in a 3-day treatment paradigm. The convulsive action of BW373U86 was also less sensitive than the antinociceptive action to treatment with the irreversible delta-antagonist naltrindole isothiocyanate. Collectively, these data suggest that the convulsive and antinociceptive activities of delta-agonists are mediated through the same receptor but that the receptor reserve for delta-mediated convulsive activity is greater than for delta-mediated antinociceptive activity.
δ-阿片受体选择性激动剂在包括小鼠在内的多个物种中可产生镇痛作用和惊厥。本文研究了小鼠中的两个假说:1)镇痛作用和惊厥活性是通过同一类型的δ-受体介导的;2)与惊厥活性相比,镇痛作用需要更高的δ-激动剂效能。在醋酸诱导的腹部收缩试验中评估δ介导的镇痛作用,该试验涉及低强度的有害刺激;惊厥活性表现为轻度强直-阵挛性惊厥发作,随后是一段僵住期。在δ-阿片受体基因敲除小鼠[DOR-1(-/-)]中,非肽类δ-激动剂(+/-)-4-[(R*)-[(2S*,5R*)-2,5-二甲基-4-(2-丙烯基)-1-哌嗪基]-(3-羟基苯基)甲基]-N,N-二乙基苯甲酰胺盐酸盐(BW373U86)和(+)-4-[(R)-[(2S,5R)-2,5-二甲基-4-(2-丙烯基)-1-哌嗪基]-(3-甲氧基苯基)甲基]-N,N-二乙基苯甲酰胺(SNC80)未能产生惊厥行为,证明DOR-1绝对参与了这一效应。在表达δ-阿片受体的NIH瑞士小鼠中,BW373U86产生了镇痛作用和惊厥活性。这些效应被假定的δ(1)-受体选择性拮抗剂7-亚苄基纳曲酮和假定的δ(2)-受体选择性拮抗剂纳曲苄拮抗。对BW373U86的惊厥和镇痛作用均产生了耐受性。在为期3天的治疗模式中,每次给予激动剂后20分钟给予拮抗剂纳曲吲哚,可在很大程度上防止对BW373U86惊厥作用的耐受性,但不能防止对其镇痛作用的耐受性。BW373U86的惊厥作用对不可逆δ-拮抗剂异硫氰酸纳曲吲哚治疗的敏感性也低于其镇痛作用。总体而言,这些数据表明,δ-激动剂的惊厥和镇痛活性是通过同一受体介导的,但δ介导的惊厥活性的受体储备大于δ介导的镇痛活性的受体储备。